Your browser doesn't support javascript.
loading
Subphenotypes of frailty in lung transplant candidates.
Singer, Jonathan P; Calfee, Carolyn S; Delucchi, Kevin; Diamond, Joshua M; Anderson, Michaela A; Benvenuto, Luke A; Gao, Ying; Wang, Ping; Arcasoy, Selim M; Lederer, David J; Hays, Steven R; Kukreja, Jasleen; Venado, Aida; Kolaitis, Nicholas A; Leard, Lorianna E; Shah, Rupal J; Kleinhenz, Mary Ellen; Golden, Jeffrey; Betancourt, Legna; Oyster, Michelle; Brown, Melanie; Zaleski, Derek; Medikonda, Nikhila; Kalman, Laurel; Balar, Priya; Patel, Shreena; Calabrese, Daniel R; Greenland, John R; Christie, Jason D.
Afiliación
  • Singer JP; Division of Pulmonary and Critical Care, Department of Medicine, University of California, San Francisco, California, USA. Electronic address: jon.singer@ucsf.edu.
  • Calfee CS; Division of Pulmonary and Critical Care, Department of Medicine, University of California, San Francisco, California, USA.
  • Delucchi K; Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, California, USA.
  • Diamond JM; Division of Pulmonary, Allergy and Critical Care Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Anderson MA; Division of Pulmonary, Allergy and Critical Care Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Benvenuto LA; Division of Pulmonary, Allergy and Critical Care Medicine, Columbia University Medical Center, New York City, New York, USA.
  • Gao Y; Division of Pulmonary and Critical Care, Department of Medicine, University of California, San Francisco, California, USA.
  • Wang P; Division of Pulmonary and Critical Care, Department of Medicine, University of California, San Francisco, California, USA; San Francisco Veterans Affairs Health Care System, San Francisco, California, USA.
  • Arcasoy SM; Division of Pulmonary, Allergy and Critical Care Medicine, Columbia University Medical Center, New York City, New York, USA.
  • Lederer DJ; Regeneron Pharmaceuticals, Tarrytown, New York, USA.
  • Hays SR; Division of Pulmonary and Critical Care, Department of Medicine, University of California, San Francisco, California, USA.
  • Kukreja J; Division of Cardiothoracic Surgery, University of California, San Francisco, California, USA.
  • Venado A; Division of Pulmonary and Critical Care, Department of Medicine, University of California, San Francisco, California, USA.
  • Kolaitis NA; Division of Pulmonary and Critical Care, Department of Medicine, University of California, San Francisco, California, USA.
  • Leard LE; Division of Pulmonary and Critical Care, Department of Medicine, University of California, San Francisco, California, USA.
  • Shah RJ; Division of Pulmonary and Critical Care, Department of Medicine, University of California, San Francisco, California, USA.
  • Kleinhenz ME; Division of Pulmonary and Critical Care, Department of Medicine, University of California, San Francisco, California, USA.
  • Golden J; Division of Pulmonary and Critical Care, Department of Medicine, University of California, San Francisco, California, USA.
  • Betancourt L; Division of Pulmonary and Critical Care, Department of Medicine, University of California, San Francisco, California, USA.
  • Oyster M; Division of Pulmonary, Allergy and Critical Care Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Brown M; Division of Pulmonary, Allergy and Critical Care Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Zaleski D; Division of Pulmonary, Allergy and Critical Care Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Medikonda N; Division of Pulmonary and Critical Care, Department of Medicine, University of California, San Francisco, California, USA.
  • Kalman L; Division of Pulmonary, Allergy and Critical Care Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Balar P; Division of Pulmonary, Allergy and Critical Care Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Patel S; Division of Pulmonary, Allergy and Critical Care Medicine, Columbia University Medical Center, New York City, New York, USA.
  • Calabrese DR; Division of Pulmonary and Critical Care, Department of Medicine, University of California, San Francisco, California, USA; San Francisco Veterans Affairs Health Care System, San Francisco, California, USA.
  • Greenland JR; Division of Pulmonary and Critical Care, Department of Medicine, University of California, San Francisco, California, USA; San Francisco Veterans Affairs Health Care System, San Francisco, California, USA.
  • Christie JD; Division of Pulmonary, Allergy and Critical Care Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Am J Transplant ; 23(4): 531-539, 2023 04.
Article en En | MEDLINE | ID: mdl-36740192
Heterogeneous frailty pathobiology might explain the inconsistent associations observed between frailty and lung transplant outcomes. A Subphenotype analysis could refine frailty measurement. In a 3-center pilot cohort study, we measured frailty by the Short Physical Performance Battery, body composition, and serum biomarkers reflecting causes of frailty. We applied latent class modeling for these baseline data. Next, we tested class construct validity with disability, waitlist delisting/death, and early postoperative complications. Among 422 lung transplant candidates, 2 class model fit the best (P = .01). Compared with Subphenotype 1 (n = 333), Subphenotype 2 (n = 89) was characterized by systemic and innate inflammation (higher IL-6, CRP, PTX3, TNF-R1, and IL-1RA); mitochondrial stress (higher GDF-15 and FGF-21); sarcopenia; malnutrition; and lower hemoglobin and walk distance. Subphenotype 2 had a worse disability and higher risk of waitlist delisting or death (hazards ratio: 4.0; 95% confidence interval: 1.8-9.1). Of the total cohort, 257 underwent transplant (Subphenotype 1: 196; Subphenotype 2: 61). Subphenotype 2 had a higher need for take back to the operating room (48% vs 28%; P = .005) and longer posttransplant hospital length of stay (21 days [interquartile range: 14-33] vs 18 days [14-28]; P = .04). Subphenotype 2 trended toward fewer ventilator-free days, needing more postoperative extracorporeal membrane oxygenation and dialysis, and higher need for discharge to rehabilitation facilities (P ≤ .20). In this early phase study, we identified biological frailty Subphenotypes in lung transplant candidates. A hyperinflammatory, sarcopenic Subphenotype seems to be associated with worse clinical outcomes.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Pulmón / Fragilidad Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Am J Transplant Asunto de la revista: TRANSPLANTE Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Pulmón / Fragilidad Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Am J Transplant Asunto de la revista: TRANSPLANTE Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos